ResMed Q1 FY27 slides: strong margins, $1B shareholder returns
ResMed (RMD) reported Q1 FY27 revenue of $1.4B, up 6% YoY, and non-GAAP EPS of $2.91, exceeding estimates. The company returned $1B to shareholders via buybacks and dividends. Margins expanded, but operating margin declined due to growth investments. ResMed launched new products and expanded partnerships, while noting potential margin pressure in Q2.
How this was made
The 30-second read
Why it matters
The earnings beat and sizable shareholder return program provide a fresh catalyst for short‑term price movement.
Market read
First‑time earnings disclosure with beat and large buyback; likely prompts short‑term buying interest.
What to watch
Life‑support device decline and inventory buildup may signal short‑term earnings drag despite the beat.
Background
ResMed's Q1 FY27 earnings were released on Oct 29 2026, highlighting revenue growth, margin expansion, and a $1B capital return.
Ticker impact
ResMed reported Q1 FY27 revenue of $1.4B and non‑GAAP EPS of $2.91, both beating expectations, and returned over $1B to shareholders.
likely modest price support as the market prices in the earnings beat and capital return program
The beat was the first public disclosure of the quarter; the $1B return program adds cash‑flow credibility and may attract short‑term buying.
Market effects
Strong margins and buyback may lift the broader sleep‑tech and medical‑device sector.
Positive for U.S. healthcare equities, limited global effect.
Modest; primarily influences U.S. listed health‑tech stocks.
Counterpoint
Margin pressure in Q2 and inventory build‑up could weigh on near‑term earnings, tempering upside.
Key entities
- companyResMed
Medical‑device and digital‑health firm (NYSE:RMD).
